Pancreatic Cancer Pill Daraxonrasib Wins FDA Nod at $39,800 a Month

A breakthrough with a steep price

For years, specialists described metastatic pancreatic cancer as one of the most hopeless diagnoses in medicine. That changed on August 26, when the Food and Drug Administration approved daraxonrasib, a once-daily pill from Revolution Medicines sold as Rasonque.36 Six weeks of coverage since then has followed two threads that pull against each other. The survival data are the best the field has produced against this disease. The price is the highest ever set for a mainstream cancer pill.

Lung cancer, the country's other leading cancer killer, is also getting new options, though more gradually. Read together, the two stories describe a pattern in oncology right now. Precision drugs are breaking into tumors once thought untreatable, regulators are moving faster than ever, and drugmakers are setting prices that test how much the healthcare system will pay for months of added life.

What the trial showed

The approval rests on RASolute 302, a global phase 3 study of 500 patients. Brian Wolpin of Dana-Farber Cancer Institute led the trial, and it covered North America, Europe, and Asia.3 Half the patients on daraxonrasib lived at least 13.2 months, compared with 6.7 months for those on standard chemotherapy. The hazard ratio of 0.40 means a 60% lower risk of death.29 Tumors shrank or disappeared in 31.6% of patients on the drug, versus 11.2% on chemotherapy.3 When the results were presented at the American Society of Clinical Oncology meeting in May, the audience gave them standing ovations, and the New England Journal of Medicine published the study the same day.411

The science matters as much as the numbers. Mutations in RAS proteins, mostly KRAS, drive more than 90% of pancreatic cancers. For decades those proteins were considered "undruggable" because their smooth surfaces gave drugs nothing to grip.1019 Earlier RAS drugs approved for lung and colorectal cancer target only one variant, KRAS G12C, which rarely drives pancreatic tumors.21 Daraxonrasib uses a different trick. It first binds a helper protein called cyclophilin A, and that pairing then grabs active RAS and shuts down its growth signals.928 Because it works against several RAS forms, the label does not require a specific mutation.5

Patients and doctors also point to how the drug fits into daily life. Wolpin has said patients no longer need five-hour infusions, chemotherapy pumps, or implanted ports, and side effects are generally milder than with chemotherapy.19 The main side effects reported include rash, diarrhea, fatigue, nausea, and painful split fingertips.28 The Pancreatic Cancer Action Network (PanCAN) now treats the drug as the standard of care for previously treated metastatic disease and notes that the trial also found better pain control and quality of life.10

The approval was unusually fast

The regulatory side is the clearest example yet of the FDA's new National Priority Voucher pilot. The program is designed to cut reviews to one or two months for drugs that address national health priorities, compared with the usual ten to twelve.2 Daraxonrasib was approved 35 days after the agency accepted the application.1 FDA oncology chief Angelo de Claro said the decision came 6.5 months ahead of the user-fee deadline.25

The coverage does not fully agree on how to describe that speed. One major outlet described the review as being cut from 12 months to 10, which does not match the 35-day figure or the FDA's own statement about the deadline.25 The more consistent account is that the voucher program shrank a process that normally takes most of a year down to about five weeks.124 The label also goes beyond the trial. It covers adults who have had at least one prior systemic therapy and also those who cannot tolerate multidrug chemotherapy, a group RASolute 302 did not test directly.5

Regulators also moved before approval. In May, the FDA allowed an expanded access program, and more than 2,000 patients received the drug free before approval. Those patients are now moving to insurance coverage.67 Here, the fast approval process and access for desperate patients worked together.

$477,000 a year, and who actually pays

According to a securities filing, Revolution priced Rasonque at about $39,800 for a 30-day supply.1 Depending on how the annual figure is calculated, outlets put it at roughly $477,000 to $478,000, with one estimate as high as about $484,000.136 That is more than double the list price of Merck's Keytruda, the world's best-selling cancer drug.1

The company's case rests on discounts and assistance. Its finance chief expects government and other discounts to bring the net price down 20% to 30%. Eligible commercially insured patients may pay as little as $0 through copay assistance, and uninsured patients who meet income limits can get the drug free.13 For older adults, who make up much of the pancreatic cancer population, the Inflation Reduction Act's Part D out-of-pocket cap matters more. It is $2,100 this year and rises to $2,400 in 2027. However, manufacturer copay help generally cannot be used by Medicare patients.4

The questions that remain are about coverage, not the science. Net prices are confidential. Two of the largest pharmacy benefit managers said they were still reviewing the drug, and it is not yet clear whether insurers will limit coverage to patients who match the trial criteria.4 Patients take the drug until it stops working, so total spending will vary widely. In the trial, the median time on treatment was about six months.4

Wall Street sees the price as justified. RBC Capital Markets analysts said the data and unmet need could support "premium pricing," and they projected eventual annual sales of $11.5 billion. Revolution's stock had risen 166% this year by approval day.2 In this writer's view, that is the real tension. With about 67,350 Americans expected to be diagnosed with pancreatic cancer this year, a price set against strong evidence still adds up to a large bill.2 Pricing it at twice the rate of the world's top-selling cancer drug signals that the industry now considers roughly six extra months of median survival in a lethal cancer worth almost any price. Coverage has treated the price as a point to examine closely rather than reflexively condemn, partly because the clinical case is so strong.4

The limits: resistance and a modest median

Daraxonrasib is not a cure, and early research shows why. Reporting on biopsies from 66 patients found the drug kills about half of cancer cells within two weeks. However, it often stops working after about seven months, as surviving cells change shape and some tumors ramp up production of KRAS itself.22 PanCAN likewise warns that not every tumor responds and that resistance often develops.10 Ongoing trials are testing the drug with chemotherapy, as a first treatment in RASolute 303, and after surgery in RASolute 304.1028 Wolpin says early data suggest the drug may work better earlier in treatment.19 If that holds, both the benefit and the total spending could grow considerably.

Lung cancer's steadier progress

Lung cancer is still the biggest cause of cancer death in the United States, with an estimated 124,990 deaths in 2026. Its death rate has been falling, however, partly because of targeted kinase inhibitors. The FDA approved two more of these for non-small cell lung cancer last quarter.21 In September, the agency allowed sevabertinib (Hyrnuo) as a first treatment for certain advanced HER2-mutant cases after tumors shrank in 75% of 69 untreated patients. A larger confirmatory trial is still underway.15 The agency also cut the required post-dose hospital monitoring for tarlatamab (Imdelltra) in small cell lung cancer from 22–24 hours to 6–8 hours.15 Researchers say T-cell engagers and antibody-drug conjugates are finally showing survival benefits in previously treated small cell disease after years without progress.16

The two diseases may soon be linked by the same drug. About 30% of non-small cell lung cancers carry RAS mutations, and daraxonrasib is already in late-stage lung testing.28 Specialists at City of Hope say the pancreatic win opens the door for other RAS-driven cancers.11

The takeaway

This writer's reading is that the science is settled and the economics are not. Daraxonrasib proves that RAS can be drugged and that the FDA's voucher pilot can deliver a major therapy within weeks. Whether patients get the full benefit now depends less on biology than on insurance decisions, prior-authorization rules, and whether a nearly $40,000 monthly price becomes the benchmark for future RAS drugs.